INTRODUCTION
Anemia is a common disorder in older individuals. The prevalence of anemia increases with age to over >20% in persons aged 85 years and over.
1;2 Approximately one fifth of older persons with anemia are considered to have anemia of inflammation, 2 previously known as anemia of chronic disease, which is commonly found in patients with infections or inflammatory disorders, such as rheumatoid arthritis, inflammatory bowel disease, cancer and chronic kidney disease. 3;4 Although the exact pathophysiological mechanism is unclear, it is likely to be mediated by immune-driven processes. 3;4 Hepcidin, a 25 amino-acid peptide hormone produced by the liver, has been hypothesized to play a crucial role in anemia of inflammation. 5;6 Hepcidin is the main regulator of iron homeostasis. 7 When more iron is needed for erythropoiesis, hepcidin production is downregulated, leading to an increased availability of iron for red blood cell production. In contrast, pro-inflammatory cytokines, particularly interleukin-6, induce the production and secretion of hepcidin. 8 Hepcidin binds to the membrane protein ferroportin, an iron efflux channel on the surface of absorptive enterocytes, macrophages and hepatocytes, and induces its internalization and degradation in lysosomes, thereby sequestering iron in the cytoplasm of these cells. 9 As a result, plasma iron levels drop rapidly. 5;6 Transgenic mice over-expressing hepcidin and mice receiving synthetic hepcidin develop mild-to-moderate microcytic, hypochromic anemia. [10] [11] [12] [13] In humans, increased hepcidin levels have also been found in diseases characterized by overt inflammation, such as rheumatoid arthritis and sepsis. [14] [15] [16] In addition, higher hepcidin levels have been found in anemic patients with chronic inflammation, 15 chronic kidney disease 17;18 and cancer. 19 Hepcidin is therefore considered to be the main mediator of anemia of inflammation. [3] [4] [5] [6] Ageing is often associated with a low-grade pro-inflammatory state. 20;21 This mild proinflammatory state is thought to elicit a chronic elevation of circulating hepcidin leading to 5 impaired availability of plasma iron, limiting hemoglobin synthesis and eventually causing anemia of inflammation. 5;6 Whether hepcidin also plays a role in anemia in older persons from the general population, is debated. In the InChianti study, a population-based study of older persons in Tuscany, Italy, urinary hepcidin levels were not higher in older individuals with anemia of inflammation. 22 However, urine hepcidin concentrations may not always accurately reflect plasma hepcidin concentrations, since urine hepcidin concentrations may also depend on glomerular filtration, tubular re-absorption, and local production by tubular epithelial cells. 5;23 Moreover, (pre)-analytical variation for urine hepcidin measurements has been found to be relatively high. 24 So far, no data are available on levels of plasma hepcidin in anemia in old age in the general population. Recently, more reliable plasma hepcidin assays have become available, 5;25 allowing us to investigate the relation between plasma hepcidin levels and anemia of inflammation in older persons in the general population.
We used data from the Leiden 85-plus Study, a population-based prospective study of older persons in Leiden, the Netherlands, to 1) explore correlates of plasma hepcidin in older persons in the general population, and 2) to investigate the role of plasma hepcidin in anemia in old age by testing two hypotheses; a) older persons with anemia of inflammation have higher levels of plasma hepcidin and b) older persons with iron deficiency anemia have lower levels of plasma hepcidin.
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DESIGN AND METHODS
Design, setting and participants
The Leiden 85-plus Study is a population-based prospective follow-up study of 85-year-old inhabitants of Leiden, The Netherlands. Between September 1997 and September 1999, 705 inhabitants of Leiden reached the age of 85 and were eligible and invited for study participation. 26 Fourteen subjects died before enrollment in the study and 92 subjects refused to participate (response 87% Participants were visited at their place of residence for face-to-face interviews, the assessment of functional tests and the collection of a venous blood sample. All participants gave their informed consent. The Medical Ethical Committee of the Leiden University Medical Center approved the study.
Laboratory measurements
Non-fasting blood samples were drawn before 11 a.m. Plasma samples were stored at -80°C.
In 2010, plasma hepcidin-25 levels at age 86 were measured in one batch by a combination of weak cation exchange chromatography and time-of-flight mass spectrometry (TOF-MS), using a Microflex LT matrix-enhanced laser desorption/ionisation (MALDI) TOF-MS platform (Bruker Daltonics, Bremen, Germany). 25 An internal standard (synthetic hepcidin-24; Peptide International Inc., Louisville, KT, USA) was used for quantification. 27 The lower limit of detection was 0.5 nM. or transferrin iron saturation was <20%. 28 When a participant fulfilled one or more of the criteria, he or she was considered to have a low iron status.
Hemoglobin and Mean Corpuscular Volume (MCV) were determined on the day the blood sample was drawn by a fully automated system (Sysmex XE-2100, TOA Medical Electronics, Kobe, Japan). Anemia was defined according to criteria of the World Health Organization (hemoglobin level <13 g/dL for men and hemoglobin <12 g/dL for women).
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Plasma levels of vitamin B12 and folate at age 86 were determined in one batch using the Dual Count Solid Phase No-Boil Assay (Diagnostic Products Corp, Los Angeles, California).
Vitamin B12 deficiency was defined as plasma vitamin B12 levels lower than 150 pmol/L; folate deficiency was defined as plasma folate levels lower than 7.0 nmol/L. 30 Plasma creatinine concentration was measured at the day the sample was drawn according to the Jaffe method with the use of a fully automated Hitachi 747 system (Hitachi, Tokyo, Japan). We estimated creatinine clearance using the Cockcroft-Gault formula. 31 Creatinine clearance <30 mL/min was considered to be low. 
Anemia subtypes
Participants with anemia were subdivided into specific subtypes of anemia according to the following criteria: 1) participants with low iron status were classified as having iron deficiency anemia; 2) participants with either vitamin B12 deficiency or folate deficiency were considered to have vitamin B12/folate deficiency anemia; 3) participants with low creatinine clearance were classified as having anemia of kidney disease; and 4) participants with either A) elevated CRP levels only, or B) elevated CRP levels and ferritin level >300 µg/L, and iron level <10 µmol/L or transferrin iron saturation <20%, were considered to have anemia of inflammation. Participants in which more than one of the abovementioned laboratory abnormalities were identified were considered to have anemia of multiple causes.
As a low iron status was hypothesized to be associated with lower plasma hepcidin levels, and the other causes of anemia with higher hepcidin levels, separate groups were constructed for those with multiple causes including iron deficiency and for those with multiple causes but normal iron status. Participants with anemia and normal iron status, normal vitamin B12, normal folate, normal renal function, and normal CRP were classified as having unexplained anemia.
Other clinical parameters
Information on the presence of disease (stroke, myocardial infarction, severe cognitive impairment, diabetes mellitus, Parkinson disease, hip fracture, arthritis, obstructive lung disease and malignant disease) was obtained from general practitioners, nursing home physicians, pharmacy records and laboratory findings. 32 Diabetes mellitus was considered present when diagnosed by the primary care physician, when non-fasting glucose levels were >11.0 mmol/L, or when a participant was taking anti-diabetic medication. The presence of severe cognitive impairment was based either on diagnosis by the general practitioner or on a
Mini-Mental State Examination (MMSE) score <19 points. 33 
Statistical analysis
Participants with hepcidin values below the detection limit of 0. We analyzed the data with PASW 17.0 for Windows (SPSS Inc., Chicago, IL). High CRP levels (>5 mg/L) were found in 169 participants (34.5%).
RESULTS
In the total study population, plasma hepcidin levels ranged from <0. p=0.58). Table 2 shows the characteristics of the study population at age 86, divided in quartiles of hepcidin. Median hemoglobin levels were similar in the four hepcidin quartiles (p=0.42).
Plasma hepcidin levels correlated with body iron status, CRP levels and levels of As hypothesized, hepcidin levels were significantly lower in participants (n=89) with low iron status than in participants (n=401) with normal iron status (median 2.0 nM [IQR 0. causes. In addition, highest serum iron levels were found in those with unexplained anemia.
Participants with anemia of kidney disease had the lowest erythropoietin levels. Highest levels of erythropoietin were observed in those with iron deficiency anemia. Erythropoietin level in the participants with unexplained anemia was 11.1 mIU/mL (IQR 7.5-13.9). 
DISCUSSION
In the present study among older persons in the general population, we found strong correlations between plasma hepcidin, and body iron status, CRP and erythropoietin. Lower hepcidin levels were found in older persons with iron deficiency anemia than in their counterparts without anemia. Higher hepcidin levels were found in anemia of inflammation, anemia of kidney disease, and unexplained anemia.
These findings concur with our hypotheses that older persons with iron deficiency anemia have lower levels of hepcidin and older persons with anemia of inflammation have higher levels of hepcidin. Our findings are in line with other studies in animals and selected human populations that show strong associations between hepcidin levels and ferritin levels and inflammatory markers. 15;16;22;25;34;35 Earlier studies have also reported lower or even undetectable hepcidin levels in iron deficiency anemia. 15;22;25;36 In contrast with the InChianti study on hepcidin measured in urine, 22 we are the first to report higher hepcidin levels in older persons in the general population with anemia of inflammation, anemia of kidney disease, and unexplained anemia. These conflicting findings between the two studies may perhaps be explained by differences in the definition of subtypes of anemia, and iron status in particular, or by differences in hepcidin measurements between the InChianti study and our study, e.g. urine vs. plasma, or total hepcidin vs. hepcidin-25, respectively.
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In our study, highest hepcidin levels were found in those participants with anemia of chronic kidney disease, perhaps because excretion and degradation of hepcidin by the kidney is hampered. 5;17 Although in previous studies patients with chronic kidney disease were mostly found to have increased plasma hepcidin levels, the association between the glomerular filtration rate and hepcidin levels in these patients has not yet been precisely estimated.
5;17;18;37
As we found erythropoietin to be highest in participants within the lowest hepcidin quartile, and vice versa, erythropoiesis or erythropoietin itself may inhibit hepcidin production.
Detailed studies are necessary to shed further light on the underlying pathophysiological mechanisms.
A combination of several age-related physiological changes are thought to contribute to the development of unexplained anemia, such as (subclinical) renal insufficiency, stem cell aging, androgen insufficiency, low-grade chronic inflammation, and myelodysplasia or other types of bone marrow failure. 2;38;39 Interestingly, we found higher levels of plasma hepcidin in those participants with unexplained anemia. Further studies should establish the underlying pathophysiological mechanism, as iron status, inflammatory status and erythropoietic markers were normal in these participants. Possibly, in unexplained anemia, bone marrow failure is associated with lower iron utilization by the developing erythrocytes, resulting in higher plasma iron concentrations and higher iron stores and consequently, with increased hepatocyte hepcidin production.
5;40
Iron is vital for micro-organisms. 41 Humans have developed several mechanisms to deprive microbes of iron during infections. [41] [42] [43] These mechanisms include an increased production of iron binding proteins such as lactoferrin, 43 but also a systemic response by rapidly lowering plasma iron concentrations, mediated by a cytokine-driven increase in hepcidin. [41] [42] [43] As such, hepcidin functions as the main regulator of iron homeostasis. [5] [6] [7] At supraphysiological concentrations, hepcidin exhibits antifungal and antibacterial activities 44 that resemble cysteine-rich antimicrobial peptides defensins and protegrins. 45 Hepcidin binds to the membrane protein ferroportin, after which duodenal enterocytes deliver less dietary iron to extracellular fluid, macrophages fail to release iron that is recycled from senescent erythrocytes and hepatocytes retain stored iron, all causing a drop in iron levels. 5;6 We found strong correlations between plasma hepcidin levels and body iron status, CRP levels and erythropoietin indicating that the regulatory mechanisms that drive hepcidin production are intact until very old age.
Strengths of the present study are its large population-based sample of older individuals and the state of the art measurement of plasma hepcidin levels instead of urinary hepcidin levels. 5;6;24 Hepcidin levels were measured more than 13 years after blood collection in non-fasting blood samples. It is as yet unknown if plasma hepcidin concentrations are directly affected by the iron content of the food that was eaten prior to the measurement. More studies have to be done on the influence of dietary intake and the diurnal rhythm of hepcidin. However, we found circadian differences in serum hepcidin levels, 24 and, in a recent study among healthy human volunteers, hepcidin-25 concentrations displayed a diurnal variation that was not influenced by food intake. 46 The stability of plasma hepcidin over longer periods is also unknown and hepcidin tends to aggregate and adhere to surfaces, and may even be oxidized or degraded. 5;6 This may have led to measurement error. However, all comparisons were within the same study population, and all samples were collected before 11 am, irrespective of anemia subtype. In addition, there is no reason to assume that iron content of the food prior to the measurement or degradation of hepcidin was different in subjects with different types of anemia. Therefore, we consider it unlikely that the relative differences presented here are due to eating habits, diurnal rhythm of hepcidin or storage conditions. However, it may impair the direct comparison with other studies using the same methodology with respect to absolute hepcidin levels.
Median hepcidin level in our study population aged 86 years (n=490) was 3.0 nM (IQR 1.8- The potential clinical value of hepcidin in future diagnostic algorithms for anemia also has to be explored, as hepcidin may help to discriminate between classic iron deficiency anemia (low hepcidin levels) and iron deficiency in the context of anemia of inflammation (high hepcidin levels). 5;6;14;48 Hepcidin may then be used to predict the therapeutic response to iron administration. 5;6 Future studies should also establish whether hepcidin antagonists, e.g. antiinterleukin-6 receptor antibodies and hepcidin-neutralizing agents, 49 or targets against the hepcidin binding site of ferroportin, have potential value in the treatment of anemia of inflammation in older persons. 
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TABLES
